Division of H. Lundbeck AS
Latest From Lundbeck Inc.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.
Novel therapeutic strategies for Parkinson’s disease have brought a renewed sense of optimism to those researching this neurodegenerative disorder. Numerous treatment avenues are being explored, including small molecules, gene therapy, cell therapy and medical devices to stimulate nerves deep in the brain. Digital also gets a look-in, being useful for analyzing gait and other symptoms, and addressing both mental and physical issues.
The Assistance Fund directed donations received from the companies to patients taking their multiple sclerosis drugs, the US Department of Justice announced. Further settlements may be pending.
Lundbeck executive calls for adaptive trial designs, transdiagnostic approach, and more scientific discussions between sponsors and the US Food and Drug Administration.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Neurology, Nervous System
- Ovation Pharmaceuticals Inc.
- North America
- Parent & Subsidiaries
- H. Lundbeck AS
- Senior Management
- Doug Carlson, Sr. Dir., Corp. BD & Strategy
- Contact Info
Phone: (800) 455-1141
4 Parkway N.
Deerfield, IL 60015
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.